Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Heidelberg Pharma AG    WL6   DE000A11QVV0

HEIDELBERG PHARMA AG (WL6)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Xetra
10/09/2018 10/10/2018 10/11/2018 10/12/2018 10/15/2018 Date
2.11(c) 2.08(c) 2.07(c) 2.03(c) 2.13 Last
80 026 23 664 75 958 48 936 12 250 Volume
-10.97% -1.42% -0.48% -1.93% +4.93% Change
More quotes
Financials (EUR)
Sales 2018 3,50 M
EBIT 2018 -11,8 M
Net income 2018 -12,0 M
Finance 2018 31,6 M
Yield 2018 -
Sales 2019 4,65 M
EBIT 2019 -12,5 M
Net income 2019 -12,6 M
Finance 2019 18,8 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 7,29x
EV / Sales2019 8,25x
Capitalization 57,1 M
More Financials
Company
Heidelberg Pharma AG engages in the development of diagnostic and therapeutic products for the detection and targeted treatment of various types of cancer.It operates through the following segments: Customer Specific Research (Cx), Diagnostics (Dx), andTherapeutics (Rx).The Customer Specific... 
More about the company
Surperformance© ratings of Heidelberg Pharma AG
Trading Rating : Investor Rating :
More Ratings
Latest news on HEIDELBERG PHARMA AG
10/11HEIDELBERG PHARMA AG : Partner Magenta Therapeutics Exercises Option To Further ..
EQ
10/11HEIDELBERG PHARMA AG : Interim management statement on the first nine months of ..
EQ
10/08HEIDELBERG PHARMA AG : quaterly sales release
09/28HEIDELBERG PHARMA AG : Release according to Article 41 of the WpHG [the German S..
EQ
09/13HEIDELBERG PHARMA AG : Release according to Article 41 of the WpHG [the German S..
EQ
09/13CORRECTION OF A RELEASE FROM 30.05.2 : 00 CET/CEST - Heidelberg Pharma AG: Relea..
EQ
09/13CORRECTION OF A RELEASE FROM 30.04.2 : 46 CET/CEST - Heidelberg Pharma AG: Relea..
EQ
08/23HEIDELBERG PHARMA AG : Partner Telix Pharmaceuticals Files Phase III Trial for K..
EQ
07/26HEIDELBERG PHARMA AG : Notification and public disclosure of transactions by per..
EQ
07/12HEIDELBERG PHARMA : reports on first half-year
EQ
More news
Sector news : Biotechnology & Medical Research - NEC
10/11GILEAD SCIENCES : Allogene's Upsized IPO Prices at High End of Range
DJ
10/05ABBVIE : Receives Health Canada Approval of Orilissa for Endometriosis Pain Trea..
DJ
10/04J&J, Arrowhead in gene-silencing drug deal worth up to $3.7 billion
RE
10/02GILEAD SCIENCES : Allogene Sets IPO at 16 Million Shares; Sees Pricing $16-$18
DJ
09/28FDA Approves Libtayo to Treat Advanced Cutaneous Squamous Cell Carcinoma
DJ
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
10/11Heidelberg Pharma AG: Partner Magenta Therapeutics Exercises Option To Furthe..
2
10/11$WL6 #Wilex AG HEIDELBERG PHARMA - Q3 18: guidance revised due to shifting co.. 
10/11Heidelberg Pharma AG: Interim management statement on the first nine months o..
1
09/28Heidelberg Pharma AG: Release according to Article 41 of the WpHG [the German.. 
09/13Heidelberg Pharma AG: Release according to Article 41 of the WpHG [the German.. 
More tweets
Qtime:8
News from SeekingAlpha
2016Deal Flurry Shines Spotlight On Novel Multiple Myeloma Target 
Chart HEIDELBERG PHARMA AG
Duration : Period :
Heidelberg Pharma AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends HEIDELBERG PHARMA AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 4,31 €
Spread / Average Target 112%
EPS Revisions
Managers
NameTitle
Jan Schmidt-Brand Chief Executive Officer & Chief Financial Officer
Christof Hettich Chairman-Supervisory Board
Andreas Pahl Head-Research & Development
Friedrich von Bohlen und Halbach Member-Supervisory Board
Georg F. Baur Deputy Chairman-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
HEIDELBERG PHARMA AG-37.52%66
CELLTRION, INC.--.--%30 463
IQVIA HOLDINGS INC27.47%24 833
LONZA GROUP18.72%23 465
INCYTE CORPORATION-33.95%13 127
SEATTLE GENETICS, INC.36.02%11 255